Oak Therapeutics and the Department of Family Medicine at the University of Kansas Medical (KUMC) Center will cooperate on the development of Oral Dissolvable Strips for pediatric HIV antiretroviral prophylaxis in Kenya. The cooperation, which will be funded by the KUM...
We are proud to announce that we have received a contract from NIAID, the National Institute of Allergy and Infectious Diseases, a division of NIH, the National Institutes of Health. The contract enables us to develop a high-dose antibiotic Oral Dissolvable Strip (ODS)...
We are proud to report that we are in the final stages of negotiating an SBIR award with the National Institute for Allergens and Infectious Diseases (NIAID). The award will allow us to develop an oral dissolvable strip for Isoniazid, a pharmaceutical used in the treat...
On Friday, February 26th, the Pacific Coast Business Times announced the winners of the 2016 Central Coast Innovation Awards. We're proud to announce that Oak Therapeutics will be honored as the winner in the BioScience category! http://www.pacbiztimes.com/2016/02/26/c...
Ed Maliski, Ph.D. recently was interviewed by entrepreneur Mark Sylvester for the 805 Conversations podcast. Among other topics, Ed speaks about his starting of Cure Pharmaceuticals, his current role in Oak Therapeutics and - most importantly - his passion for providin...
Yesterday, a much-anticipated announcement was made on a variety of media outlets – European regulators approved Mosquirix, the first-ever malaria vaccine. Although this is an important first step, it is not the final blow to a disease that infects hundreds of millions...
We've had a pretty neat folder that describes what Oak Therapeutics is about for quite a while. This folder is now also online as a flip book. Check it out!
In it's July 3-9 edition, the Pacific Cost Business Times reported on the pre-clinical study that we just completed on our malaria product, Artelutrine, a combination of active ingredients Artemisinin and Lumefantrine.
We just released our new video on our contribution to solving the malaria problem. Our gratitude goes to Dariush Apfelthaler (vide0) as well as David "Blaze" Sepowski and David Decker (music). The video is available on YouTube.
Fresh from PR Log: Oxnard, CA – Oxnard-based pharmaceutical start-up Oak Therapeutics successfully concluded the pre-clinical phase of its anti-malarial medication Artelutrine™. Artelutrine™ is a reformulation of a highly effective, WHO-recommended combination therapy...
All of us at Oak Therapeutics are extremely proud to announce that we just concluded initial preclinical testing of our anti-malarial medication Artel...
OAK THERAPEUTICS SUCCESSFULLY CONCLUDES TRIAL OF MALARIA MEDICATION
